Compound ID | 84
Class: Beta-lactam (carbapenem)
| Spectrum of activity: | Gram-negative |
| Details of activity: | MDR gram-negative infections |
| Institute where first reported: | AstraZeneca (UK) + FOB Synthesis, Inc (USA) |
| Year first mentioned: | 2014 |
| Highest developmental phase: | Preclinical |
| Development status: | Experimental |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/76192363 |
| Citations: |
|